32 results about "Topical anaesthetic" patented technology

The invention discloses an application of an N-acetanilide cationic compound in preparation of a local nerve blocking drug. The cationic compound is a quaternary ammonium salt compound and has a structure as shown in a formula (I), wherein X is a halogen atom. When used alone, the compound has the characteristics of good safety performance, strong nerve blocking effect and the like, can take a reversible and durable local anaesthesia effect in vivo and can be used as a local anaesthesia drug or an analgesic drug which is long-acting and / or capable of realizing selective blocking. Particularly, a composition composed of the compound and other local anaesthesia drugs has the remarkable characteristics of high effect taking speed, strong effect, long acting time, little nerve injury and the like when used for nerve blocking.

An oral rinse formulation for the treatment or prophylaxis of mucositis or stomatitis comprises one or more of the following components in combination with pharmaceutically acceptable excipients or additives: a) at least one corticosteroid; b) at least one anti-histamine; c) at least one topical anaesthetic; and, d) at least one anti-fungal antibiotic agent. A stable nystatin containing formulation is also provided comprising a buffering agent, a preservative, a chelating agent and an anti-oxidant.

An oral rinse formulation for the treatment or prophylaxis of mucositis or stomatitis comprises one or more of the following components in combination with pharmaceutically acceptable excipients or additives: a) at least one corticosteroid; b) at least one anti-histamine; c) at least one topical anaesthetic; d) at least one antibiotic agent; and, e) at least one anti-fungal antibiotic agent. A method of treating or preventing mucositis or stomatitis using such formulation is provided.

The invention relates to a medicinal composition for treating canker sore and local infection of body surface and reducing inflammation, a product and application thereof. The medicinal composition comprises aminoglycoside antibiotics, local anaesthetics and glucocorticoids in weight ratio of (0.1-10):(1-10):(0.01-10). Compared with the prior art, the medicinal composition has the advantages that local anaesthetics can alleviate pains of patients in time; antibiotics has the antibiotic effect of treating infection caused by bacteria; and the glucocorticoids has the anti-inflammatory effect of reducing focus hyperemia, reducing permeability of capillary and inhibiting inflammatory cells from transferring to the inflammatory part; and the synergistic action of the three medicaments promotes the healing of canker sore so as to achieve good treatment effect.

The invention discloses a composite nanocapsule-injectable hydrogel double-drug-loading sustained release system, comprising a nanocapsule used for encapsulating a drug, and injectable hydrogel, wherein the average particle size of the nanocapsule is 100nm-1000nm, and the weight volume ratio of the composite nanocapsule to the injectable hydrogel is (1 to 1) to (1 to 10); the injectable hydrogel is prepared from a high molecular polymer and a crosslinking agent; the nanocapsule is prepared from a high molecular base material; a local anesthetic, a nerve repair drug or a contrast medium can be encapsulated in the nanocapsule, so that the effect of slowly releasing the drug is achieved; injectable hydrogel matrix in the double-drug-loading sustained release system can be used for locating a nanocapsule carrier in a human body, so that the whole drug sustained release system is fixed at the site of lesion, and the long-term slow release treatment for the site of lesion is facilitated. The composite nanocapsule-injectable hydrogel double-drug-loading sustained release system has good application prospects in the fields such as analgesia, tumor therapy, local anaesthesia and nerve repair which need local long-term drug slow release.

The invention provides a lidocaine medicine composition for preparing local anesthetic for preventing or treating surgical pain of human and mammals, and application of the lidocaine medicine composition in preparation and application of a medicine. Therefore, a corresponding product has a quicker and better treating effect, higher safety and higher treating compliance in a clinical process.

The invention relates to the technical field of daily consumer goods for killing malignant bacteria, viruses and funguses in oral cavity and throat, cleaning the oral cavity and preventing and treating oral diseases, and in particular relates to nano-silver mouth wash for preventing and treating oral diseases and a preparation method thereof. The mouth wash is characterized by comprising 0.1ppm-1000ppm nano silver and the following components in percentage by weight: 0.01-5% of a hemostatic, 0.01-5% of a topical anaesthetic, 0.01-10% of a bacteriostatic agent, 0.1-25% of a dispersant, 0.1-25% of a thickener, 0.1-15% of a wetting agent, 0.1-10% of an algefacient, 0.1-35% of an adhesive agent, 0.01-5% of a corrigent and 0.01-5% of a colorant. The principle is as follows: silver particles with diameter of 10-50 nanometers can be absorbed to cytomembranes of harmful microorganisms to damage protein capsids and DNA (Deoxyribonucleic Acid) molecules of the harmful microorganisms to lead to death of the harmful microorganisms by interfering metabolism of the harmful microorganisms, so that the nano-silver mouth wash has broad spectrum sterilizing and bacteriostatic effect, is durable and effective in effect, free from toxic and side effects as well as drug resistance, safe and reliable, convenient to use, simple in production and preparation, and has very good preventing and treating effect to periodontal disease, acute and chronic aryngitis and oral mucosal diseases.

The invention provides a membrane-spraying agent for superficial burns and a preparation method thereof and relates to the field of medical science. The membrane-spraying agent is prepared from, by weight, flamazine, antibacterial agents, epidermal growth factors, topical anaesthetics, borneol, lithospermum extract liquid, radix angelicae extract liquid, golden cypress extract liquid, polygonum cuspidatum extract liquid, membrane-forming agents, glycerinum and the balance water. The preparation method includes the steps that firstly, the topical anaesthetics, the borneol and the epidermal growth factors are dissolved in a water solution of the glycerinum; then, the flamazine, the antibacterial agents and the membrane-forming agents are dissolved in a small amount of water; finally, the mixture is evenly mixed with the lithospermum extract liquid, the radix angelicae extract liquid, the golden cypress extract liquid, the polygonum cuspidatum extract liquid and the balance water, and the membrane-spraying agent is obtained. By means of the membrane-spraying agent, pain can be relieved rapidly, high sterilization and disinfection functions are achieved, and the position of burns can be recovered more rapidly. Compared with traditional ointment, the membrane-spraying agent is convenient to use and suitable for superficial burns.

The present invention is directed to a novel topical pharmaceutical water-in-oil composition in form of a cream or lotion, comprising (i) 2-50% of a local anaesthetic in oil form in the final composition, or two or more local anaesthetics forming an oil when mixed together, effective to produce a topical anaesthetic effect upon administration; (ii) 2-50% of a water-in-oil emulsifier, effective to produce an emulsion of the desired viscosity; and (iii) 2-96% water. Optionally the composition may contain up to 20% of pharmaceutically acceptable stabilizers or penetration enhancers. This novel pharmaceutical composition is useful in therapy, in particularly for the treatment of pain.

The invention relates to a cardio-pulmonary resuscitation method for cardiac arrest caused by a poisonous dose of a long-acting amide-type local anesthetic, specifically to application of levosimendan in preparation of a drug for cardio-pulmonary resuscitation after cardiac arrest caused by poisoning of the long-acting amide-type local anesthetic and a cardio-pulmonary resuscitation therapy. Through application of levosimendan in preparation of the drug for cardio-pulmonary resuscitation after cardiac arrest caused by poisoning of the long-acting amide-type local anesthetic and the cardio-pulmonary resuscitation therapy provided by the invention, a cardio-pulmonary resuscitation effect on cardiac arrest caused by clinical anaesthesia of the long-acting amide-type local anesthetic is substantially improved, and the problems of rapid exacerbation of blood-oxygen exchange in the lung and generation of the side effects of severe pneumorrhagia and acidosis in conventional treatment of bupivacaine clinical anaesthesia-induced cardiac arrest by using the scheme of combined usage of a lipid emulsion and epinephrine are overcome; moreover, the cardio-pulmonary resuscitation therapy employs combination of the lipid emulsion and levosimendan, and the incidence rate of arrhythmia occurred after combined usage of the lipid emulsion and levosimendan is substantially lower than the incidence rate of arrhythmia occurred after combined usage of the lipid emulsion and epinephrine.

The invention provides a pain-relieving and anti-inflammatory compound sustained-release preparation, which comprises a local anesthetic, a non-steroidal anti-inflammatory drug and a sustained-release preparation consisting of poloxamer 407 and poloxamer 188. The pain-relieving and anti-inflammatory compound sustained-release preparation disclosed by the invention is a non-opioid analgesic, is a dual-effect combined product composed of the local anesthetic and the low-dose non-steroidal anti-inflammatory drug, is specially used for treating postoperative pain and inflammation at an operative site through single administration, and has obvious advantages in efficacy, wherein the non-steroidal anti-inflammatory drug not only has an anti-inflammatory effect, but also can inhibit the formation of an acid environment and normalize the pH value, so that the permeation effect of the local anesthetic is recovered and enhanced, and the drug effect is as long as 4-5 days.

The invention relates to a medical tracheal catheter, in particular to a multifunctional drug eluting coating layer on the surface of the medical tracheal catheter and a preparation method of the multifunctional drug eluting coating layer. According to the preparation method, a degradable polymer drug-loaded coating is uniformly sprayed on the surface of the tracheal catheter by adopting an atomization spraying method. The coating layer comprises 50%-99.8% of a degradable polymer, 0.2%-50% of one or more of a local anesthetic a, an anti-inflammatory drug b and an anti-infective drug c. The drug eluting coating layer prepared by the method can realize independent or simultaneous loading of the local anesthetic drug, the anti-inflammatory drug and the anti-infective drug. The coating layer can inhibit bucking reaction, local inflammatory edema, infection and other adverse reactions caused by tracheal intubation by controlling release of carried drugs, reduce the risk of complications andimprove the comfort of patients.

The invention relates to the field of pharmaceutic preparations, in particular to a lipidosome-polymer particle preparation of topical anaesthetic and a preparation method of the lipidosome-polymer particle preparation. The lipidosome-polymer particle preparation of the topical anaesthetic is prepared from, by mass, 150-250 parts of topical anaesthetic, 300-350 parts of PLGA, 100-150 parts of stabilizer, 400-430 parts of phospholipid and 100-105 parts of cholesterol. The preparation is small in grain size, stable in property and good in release effect. The average grain size of the preparation is 40.15 micrometers, and the encapsulation rate is 81.8%. After dissolution rate inspection is carried out for 72 hours in a buffer salt medium with the pH of 7.4, the dissolution rate exceeds 80%. Besides, the preparation is placed for 10 days at the temperature of 30 DEG C, and the permeability does not exceed 15% and is superior to that in the prior art. In addition, the preparation method of the preparation is simple, the requirement for production equipment is not high, and the production period is short.

The invention belongs to the technical field for applying a nanometer magnetic carrier material to medical treatment. Specifically, local anaesthetic and / or antibacterial anti-inflammation drug, anti-tumor drug, antifoaming agent and the like are added into the nanometer magnetic carrier material, particularly into the magnetic liquid, thereby achieving the use for assisting the gastroscopy and treating the inflammation and the tumor diseases of the throat. The invention can magnetically control the drug, locates the throat, can adjust the time, has good anesthesia and treatment effect, has less drug use amount and small side effect, has the performance characteristics of simple operation and low examination fee, and has the applying characteristics of wide material resource, simple manufacture technology and easy industrial production.

Filmogenic compositions are described for topical anaesthetic bioadhesives (TABs) comprising a) a xanthan biopolymer matrix selected from Xanthomonas species and pathovars, including Xanthomonas campestris pathovars campestris and maninhotis, and Xanthomonas arboricola pathovar pruni, a producer of pruni xanthan, wherein the matrix is made of pure or combined xanthan varieties in any proportion, said matrix comprising between 1% and 95% by weight of the total weight of the composition, and additives or excipients; b) at least one anaesthetic, in a proportion of 0.1% to 50% by weight of the total weight of the composition. The topical anaesthetic bioadhesives (TABs) are also described, and they may be applied to the gingival mucosa and / or alveolar mucosa on the buccal (1) or lingual / buccal (2) surfaces with extensions and anatomical contours for crowns of the upper and lower dental arches.

The present invention relates to the technical field of dyes for marking organic tissue. It relates to a dye whose composition contains pigments, topical anaesthetics and absorption potentiator, used to visually mark a specific area of the surface of the organic tissue and concomitantly anaesthetize the marked area. The anaesthetic dye can be applied with a pen / stick. The invention simplifies procedures that require the marking of an anaesthetized region for subsequent intervention, saving time and anaesthetic and providing greater safety for patients. A method for applying said composition is also provided.

The invention relates to the field of pharmaceutical preparations and discloses a topical preparation of a local anesthetic drug and a method for improving the stability of the preparation of the local anesthetic drug. A local anesthetic external preparation comprises a local anesthetic and a packaging material, wherein that packaging material is a polyester / aluminum / cycloolefin composite aluminumfilm. The polyester / aluminum / cycloolefin composite aluminum film is a novel composite low-absorption packaging material. A method for improving that stability of a local anesthetic drug preparation comprises packaging the local anesthetic drug preparation with a polyester / aluminum / cycloolefin composite aluminum film as a packaging material. The method of the invention does not need to add any antioxidant or nitrogen filling, and the vacuum pumping operation is simple and convenient. Experiments show that the polyester / aluminum / cycloolefin composite aluminum film is used for packaging of topical preparations of local anesthetic drugs, the content of active drugs in the preparations can be ensured, and the stability of local anesthetic drugs can be effectively improved.

The invention discloses a pharmaceutical preparation, a system containing the pharmaceutical preparation and a preparation method and an application of the pharmaceutical preparation. The pharmaceutical preparation comprises water, a pH buffer solution and local anesthetics, wherein the local anesthetics in the pharmaceutical preparation comprise dissolved and undissolved local anesthetics, wherein the mass percentage of the local anesthetic in the pharmaceutical preparation is 2% or above; the pH buffer solution enables the mass percentage of the dissolved local anesthetic in the pharmaceutical preparation to be 1% or below; the local anesthetic is lidocaine, tetracaine, bupivacaine, articaine, cinchocaine, dibucaine, etidocaine, levobupivacaine, mepivacaine, prilocaine, ropivacaine, trimecaine, benzocaine, or procaine; and the sum of the mass percentages of the components in the medicinal preparation is 100%. In many analgesic applications, the pharmaceutical formulation is capable of obtaining a continuous analgesic effect of 6, 12, 18, 24, 36, or even 48 hours or more.

The invention discloses bupivacaine and a preparation method of an intermediate (S)-2-piperidinecarboxylic acid of the bupivacaine; wherein the intermediate (S)-2-piperidinecarboxylic acid is prepared by taking (R)-4-benzyl-2-oxazolidinone as a chiral auxiliary agent through amidation, asymmetric alkylation, hydrolysis, cyclization and auxiliary group removal; wherein the prepared (S)-2-piperidinecarboxylic acid is used as a raw material to prepare the local anesthetic (S)-bupivacaine. The method utilizes cheap and easily available organic raw materials, and has the advantages of simple operation, mild reaction conditions, good stereoselectivity, high yield and the like.

The invention relates to a liposome containing a local anesthetic and a preparation method thereof. Specifically, the present disclosure relates to liposomes comprising (1) a lipid comprising at least one phospholipid, and (2) a free base of a local anesthetic; and a hydrating fluid comprising a pharmaceutically acceptable salt, complex or chelate of a local anesthetic, the liposome having improved release properties.

The invention provides a self-assembled oligopeptide capable of inducing biological mineralization of a local anesthetic and a long-acting local anesthesia and analgesia medicinal preparation prepared from the self-assembled oligopeptide, and belongs to the field of pharmacy. According to the oligopeptide disclosed by the invention, the self-assembled nanostructure with negative charges on the surface is combined with local anesthetic molecules through the charge effect, and the local anesthetic is induced to be biomineralized under the condition that the alkaline pH regulator is used as an auxiliary agent, so that uniform micron-level injectable drug crystals are formed. The medicine crystal is used as a medicine preparation, has good biocompatibility, can effectively delay the release rate of the medicine and prolong the local anesthesia and analgesic effects, and has good application prospects in preparation of medicines with long-acting local anesthesia and long-acting analgesic effects.

The present invention relates to a method for manufacturing a pre-filling type syringe comprising a hyaluronic acid hydrogel containing a local anesthetic and a pre-filling type syringe manufactured thereby and, more specifically, to a pre-filling type syringe and a method for manufacturing the same, wherein a local anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof is allowed to be adsorbed on an inner wall of a syringe and then coated on a hydrogel surface, thereby exhibiting an excellent initial release of the local anesthetic or pharmaceutically acceptable salt thereof at the time of operation or injection, so that the syringe of the present invention can exhibit an anesthetic effect promptly at the time of injection of a skin filler or the like even when distributed and stored for a long time.

The present invention relates to a local anesthetic sustained-release preparation and preparation method using phospholipid-miscible solvent-oil as a carrier. The sustained-release preparation includes: a local anesthetic as an active ingredient, and a phospholipid-as a sustained-release drug delivery system. The mixture of miscible solvent-oil, and optionally can also include antioxidant; Wherein, described local anesthetic is selected from: one of bupivacaine or ropivacaine free base or the mixture of both; Described The miscible solvent is a mixture of benzyl benzoate, benzyl alcohol, ethanol or both; the antioxidant is vitamin E acetate and lipoic acid etc.; in the mixture of phospholipid-miscible solvent-oil, the phospholipid content is no more 50%, benzyl benzoate content is not less than 10%, and the rest is oil.

Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.

The invention discloses a medical transformation formula, a kit, a transformation method and an application of the transformation formula. The transformation formula is a solution with the pH not lessthan 10 and includes water and an alkaline substance. The final formula is obtained by mixing the transformation formula with a preparation containing local anesthetics, wherein the dosage of the transformation formula makes the pH value of the final formula be 6.5-13, and the mass percentage of amide local anesthetics or ester local anesthetics in the final formula is 0.5% or more or 0.1% or more respectively. The transformation formula can conveniently transform a conventional preparation containing local anesthetics into a transdermal absorption preparation or a sustained-release preparation. The transdermal absorption preparation can anesthetize intact skin in 120 min and anesthetize the whole face skin in 30 min. The sustained-release preparation is directly applied on the human surface without the barrier function the same as the intact skin, the effective ingredients can be released slowly, and thus the duration time of the drug efficacy is prolonged.

The present invention is directed to a novel topical pharmaceutical water-in-oil composition in form of a cream or lotion, comprising (i) 2-50% of a local anaesthetic in oil form in the final composition, or two or more local anaesthetics forming an oil when mixed together, effective to produce a topical anaesthetic effect upon administration; (ii) 2-50% of a water-in-oil emulsifier, effective to produce an emulsion of the desired viscosity; and (iii) 2-96% water. Optionally the composition may contain up to 20% of pharmaceutically acceptable stabilizers or penetration enhancers. This novel pharmaceutical composition is useful in therapy, in particularly for the treatment of pain.

The invention discloses a method for rapidly detecting caine local anesthetics added in cosmetics, and belongs to the technical field of medicine detection. The method comprises the following steps: mixing a to-be-detected cosmetic with an organic extraction reagent and a protein precipitant to obtain a protein precipitate and a supernatant, mixing the supernatant with nano sol and an enhancing aid, and testing the surface enhanced Raman spectrum of the mixture; the nano sol comprises metal nano sol, and the reinforcing auxiliary agent comprises haloid. Whether the caine local anesthetics are added into the cosmetics or not can be rapidly detected on site, and therefore the detection precision and the detection efficiency are improved at the same time.